Skip to main content

Oxprenolol









Oxprenolol


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search








































































































Oxprenolol
Oxprenolol.svg
Clinical data

AHFS/Drugs.com
 Micromedex Detailed Consumer Information
Pregnancy
category


  • AU: C


Routes of
administration		 oral
ATC code

  • C07AA02 (WHO)
Legal status
Legal status

  • In general: ℞ (Prescription only)

Pharmacokinetic data
Bioavailability 20-70%
Metabolism Hepatic
Elimination half-life
 1-2hours
Excretion
Renal
Lactic (in lactiferous females)
Identifiers
CAS Number

  • 6452-71-7 ☑Y

PubChem CID
  • 4631
IUPHAR/BPS
  • 7255
DrugBank

  • DB01580 ☒N
ChemSpider

  • 4470 ☑Y
UNII
  • 519MXN9YZR
KEGG

  • D08318 ☑Y
ChEMBL

  • ChEMBL546 ☑Y
ECHA InfoCard
100.026.598 Edit this at Wikidata
Chemical and physical data
Formula
C15H23NO3
Molar mass 265.348
3D model (JSmol)
  • Interactive image
Chirality Racemic mixture

.mw-parser-output .nobold{font-weight:normal}
 ☒N☑Y (what is this?)
  (verify)

Oxprenolol (brand names Trasacor, Trasicor, Coretal, Laracor, Slow-Pren, Captol, Corbeton, Slow-Trasicor, Tevacor, Trasitensin, Trasidex) is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris, abnormal heart rhythms and high blood pressure.


Oxprenolol is a lipophilic beta blocker which passes the blood–brain barrier more easily than water-soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than beta blockers with more hydrophilic molecules such as atenolol, sotalol and nadolol.[1]


Oxprenolol is a potent beta blocker and should not be administered to asthmatics under any circumstances due to their low beta levels as a result of depletion due to other asthma medication, and because it can cause irreversible, often fatal, airway failure and inflammation.[2]




Contents






  • 1 Pharmacology


    • 1.1 Pharmacodynamics




  • 2 Chemistry


    • 2.1 Stereochemistry




  • 3 References





Pharmacology[edit]



Pharmacodynamics[edit]


Oxprenolol is a beta blocker. In addition, it has been found to act as an antagonist of the serotonin 5-HT1A and 5-HT1B receptors with respective Ki values of 94.2 nM and 642 nM in rat brain tissue.[3]



Chemistry[edit]



Stereochemistry[edit]


Oxprenolol is a chiral compound, the beta blocker is used as a racemate, e. g. a 1:1 mixture of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol. Analytical methods (HPLC) for the separation and quantification of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol in urine and in pharmaceutical formulations have been described in the literature.[4]





(R)-(+)-Oxprenolol (top) and (S)-(–)-oxprenolol





References[edit]





  1. ^ McDevitt DG (1987). "Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs". Eur. Heart J. 8. Suppl M: 9–14. doi:10.1093/eurheartj/8.suppl_M.9. PMID 2897304..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ I P Williams and F J Millard (1980). "Severe asthma after inadvertent ingestion of oxprenolol". Thorax. 35 (2): 160. doi:10.1136/thx.35.2.160. PMC 471246. PMID 7376124.


  3. ^ Langlois M, Brémont B, Rousselle D, Gaudy F (1993). "Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors". Eur. J. Pharmacol. 244 (1): 77–87. doi:10.1016/0922-4106(93)90061-d. PMID 8093601.


  4. ^ Abounassif, Mohammed A.; Hefnawy, Mohammed M.; Mostafa, Gamal A. E. (2011). "Separation and quantitation of oxprenolol in urine and pharmaceutical formulations by HPLC using a Chiralpak IC and UV detection". Monatshefte für Chemie - Chemical Monthly. 143 (3): 365. doi:10.1007/s00706-011-0605-4.
















Retrieved from "https://en.wikipedia.org/w/index.php?title=Oxprenolol&oldid=831196233"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.884","walltime":"1.081","ppvisitednodes":{"value":5128,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":337340,"limit":2097152},"templateargumentsize":{"value":5009,"limit":2097152},"expansiondepth":{"value":16,"limit":40},"expensivefunctioncount":{"value":3,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":12252,"limit":5000000},"entityaccesscount":{"value":3,"limit":400},"timingprofile":["100.00% 670.934 1 -total"," 69.92% 469.130 1 Template:Drugbox"," 50.49% 338.746 1 Template:Infobox"," 18.52% 124.259 1 Template:Reflist"," 16.54% 110.950 19 Template:Navbox"," 15.80% 105.999 16 Template:Unbulleted_list"," 15.79% 105.937 4 Template:Cite_journal"," 6.80% 45.638 1 Template:Serotonin_receptor_modulators"," 5.61% 37.613 1 Template:Infobox_drug/chemical_formula"," 3.65% 24.486 1 Template:EditAtWikidata"]},"scribunto":{"limitreport-timeusage":{"value":"0.249","limit":"10.000"},"limitreport-memusage":{"value":4450872,"limit":52428800}},"cachereport":{"origin":"mw1331","timestamp":"20181215043216","ttl":1900800,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":113,"wgHostname":"mw1325"});});
-